UNSPSC 51285604: Delmopinol hydrochloride

This classfication denotes a surface-active agent with the molecular formula C16H33NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SRE423V9Z9, chemically known as 4-morpholineethanol, 3-(4-propylheptyl)-, hydrochloride (1:1), but more generally known as delmopinol hydrochloride, which bears U.S. National Institutes of Health Compound Identifier 57337. European Medicines Agency schedules delmopinol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06956MIG.

Most nations, for tariff purposes, schedule delmopinol hydrochloride under HS 29349990. SMILES: CCCC(CCC)CCCC1COCCN1CCO.CL.

UNSPSC 51285604 Delmopinol hydrochloride is a Commodity code that nominally designates a specific chemical antiseptic agent, but the recent state and local opportunities tagged under it show minimal direct alignment with that narrow product specification. The code appears in a procurement environment where state and local health agencies, fire departments, and cooperative purchasing organizations are sourcing a broader mix of pharmaceutical products, medical supplies, and pharmacy benefit services rather than delmopinol hydrochloride specifically. Issuing bodies include county health departments (Seminole County, Florida), municipal fire services (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The practical scope spans naloxone and drug deactivation systems, medical and first aid supplies for emergency response, generic pharmaceuticals and over-the-counter products for health facilities, and exploratory direct-to-manufacturer pharmacy programs.

Recent activity reflects geographic spread across Florida, Texas, Minnesota, and Oregon, with issuing bodies ranging from single-county operations to multistate consortia. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems delivered quarterly; the City of Tampa's IFB 26P00145 (due March 13, 2026) for 169 line items of medical and first aid supplies with an estimated contract value of $700,000 and a sheltered small local business enterprise set-aside with a 5 percent bid discount not to exceed $10,000; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products supplied through three authorized wholesalers effective July 1, 2026; and the Texas HHS Commission's RFI HHS0017013 (due April 3, 2026) exploring direct-to-manufacturer prescription programs outside existing pharmacy benefit manager arrangements. The code shows activity concentrated in health procurement and emergency services but limited direct relevance to delmopinol hydrochloride as a distinct product line.